EA201791550A1 - Димеры бензодиазепинов, их конъюгаты и способы их получения и применения - Google Patents
Димеры бензодиазепинов, их конъюгаты и способы их получения и примененияInfo
- Publication number
- EA201791550A1 EA201791550A1 EA201791550A EA201791550A EA201791550A1 EA 201791550 A1 EA201791550 A1 EA 201791550A1 EA 201791550 A EA201791550 A EA 201791550A EA 201791550 A EA201791550 A EA 201791550A EA 201791550 A1 EA201791550 A1 EA 201791550A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- application
- dymeras
- benzodiazepins
- conjugates
- reception
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Димеры бензодиазепина, имеющие структуру, представленную формулойгде Rобозначаетгде переменные в формулах (I), (Ia) и (Ib) имеют значение по определению в данной заявке. Такие димеры применимы в качестве противораковых агентов, в особенности, если они применяются в виде конъюгата антитело-лекарственное средство (ADC).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562103157P | 2015-01-14 | 2015-01-14 | |
US201562215928P | 2015-09-09 | 2015-09-09 | |
PCT/US2016/013136 WO2016115191A1 (en) | 2015-01-14 | 2016-01-13 | Benzodiazepine dimers, conjugates thereof, and methods of making and using |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201791550A1 true EA201791550A1 (ru) | 2017-11-30 |
Family
ID=55305072
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201791550A EA201791550A1 (ru) | 2015-01-14 | 2016-01-13 | Димеры бензодиазепинов, их конъюгаты и способы их получения и применения |
Country Status (19)
Country | Link |
---|---|
US (4) | US9527871B2 (ru) |
EP (1) | EP3245213B1 (ru) |
JP (1) | JP6498773B2 (ru) |
KR (1) | KR20170102980A (ru) |
CN (1) | CN107428780B (ru) |
AU (1) | AU2016206798A1 (ru) |
BR (1) | BR112017014599A2 (ru) |
CA (1) | CA2973354A1 (ru) |
CL (1) | CL2017001824A1 (ru) |
CO (1) | CO2017008078A2 (ru) |
EA (1) | EA201791550A1 (ru) |
ES (1) | ES2783624T3 (ru) |
IL (1) | IL253402A0 (ru) |
MX (1) | MX2017009145A (ru) |
PE (1) | PE20171184A1 (ru) |
SG (1) | SG11201705646XA (ru) |
TW (1) | TW201632531A (ru) |
WO (1) | WO2016115191A1 (ru) |
ZA (1) | ZA201704738B (ru) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6676058B2 (ja) * | 2015-01-14 | 2020-04-08 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | ヘテロアリーレン架橋したベンゾジアゼピン二量体、そのコンジュゲート、ならびに製造および使用方法 |
US9504694B2 (en) * | 2015-03-19 | 2016-11-29 | Cellerant Therapeutics, Inc. | Isoquinolidinobenzodiazepines |
US20190218294A1 (en) | 2016-09-09 | 2019-07-18 | Bristol-Myers Squibb Company | Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment |
WO2018053552A2 (en) * | 2016-09-19 | 2018-03-22 | Cellerant Therapeutics, Inc. | Isoquinolidinobenzodiazepines |
EP3522932A4 (en) * | 2016-10-10 | 2020-06-24 | Cellerant Therapeutics, Inc. | ISOCHINOLIDINOBENZODIAZEPINE (IQB) -1 (CHLORMETHYL) -2,3-DIHYDRO-1-H-BENZO [E] INDOL (CBI) DIMERS |
US10398783B2 (en) | 2016-10-20 | 2019-09-03 | Bristol-Myers Squibb Company | Antiproliferative compounds and conjugates made therefrom |
TWI763771B (zh) | 2017-01-25 | 2022-05-11 | 美商伊繆諾金公司 | 製備細胞毒性苯二氮平衍生物之方法 |
TW201839001A (zh) * | 2017-04-20 | 2018-11-01 | 美商伊繆諾金公司 | 細胞毒性苯并二氮平衍生物及其綴合物 |
JP2020531430A (ja) | 2017-08-16 | 2020-11-05 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 抗体を標的とする抗ctla4プロボディ療法 |
GB201714115D0 (en) | 2017-09-04 | 2017-10-18 | Femtogenix Ltd | Cytotoxic agents |
SG11202001430SA (en) | 2017-09-29 | 2020-04-29 | Daiichi Sankyo Co Ltd | Antibody-pyrrolobenzodiazepine derivative conjugate |
CN113444111A (zh) | 2018-05-29 | 2021-09-28 | 尹图赛利有限公司 | 新型苯二氮杂䓬衍生物及其用途 |
KR20210068591A (ko) * | 2018-10-31 | 2021-06-09 | 주식회사 인투셀 | 융합된 헤테로시클릭 벤조디아제핀 유도체 및 그의 용도 |
EP3882349A4 (en) | 2018-11-14 | 2023-04-05 | Daiichi Sankyo Company, Limited | (ANTI-CDH6 ANTIBODY)-(PYRROLOBENZODIAZEPINE DERIVATIVE) CONJUGATE |
KR20210098488A (ko) | 2018-11-30 | 2021-08-10 | 브리스톨-마이어스 스큅 컴퍼니 | 글루타민-함유 경쇄 c-말단 연장부를 포함하는 항체, 그의 접합체, 및 방법 및 용도 |
US20220031860A1 (en) | 2018-12-12 | 2022-02-03 | Bristol-Myers Squibb Company | Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses |
GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
KR20210143237A (ko) | 2019-03-25 | 2021-11-26 | 다이이찌 산쿄 가부시키가이샤 | 항체-피롤로벤조디아제핀 유도체 컨쥬게이트 |
JPWO2020196475A1 (ru) | 2019-03-25 | 2020-10-01 | ||
US20220168438A1 (en) | 2019-03-27 | 2022-06-02 | Daiichi Sankyo Company, Limited | Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor |
WO2020251878A1 (en) | 2019-06-11 | 2020-12-17 | Bristol-Myers Squibb Company | Anti-ctla4 antibody prodruggable (probody) at a cdr position |
WO2021055306A1 (en) | 2019-09-16 | 2021-03-25 | Bristol-Myers Squibb Company | Dual capture method for analysis of antibody-drug conjugates |
JP2024503657A (ja) | 2021-01-13 | 2024-01-26 | メモリアル スローン-ケタリング キャンサー センター | 抗体-ピロロベンゾジアゼピン誘導体コンジュゲート |
CN113372245B (zh) * | 2021-06-17 | 2023-01-13 | 仪征市海帆化工有限公司 | 一种n-苯甲酰基-o,o-对甲苯磺酰基-二乙醇胺的合成方法 |
WO2023037237A1 (en) * | 2021-09-09 | 2023-03-16 | Wavelength Enterprises Ltd | Process for the preparation of remimazolam |
KR20240073035A (ko) * | 2021-09-30 | 2024-05-24 | 아지노모토 가부시키가이샤 | 항체 및 기능성 물질의 컨쥬게이트 또는 그 염, 및 그 제조에 사용되는 항체 유도체 및 화합물 또는 그 염 |
TW202334238A (zh) | 2021-11-30 | 2023-09-01 | 日商第一三共股份有限公司 | 蛋白酶分解性遮蔽抗體 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU757510C (en) | 1998-08-27 | 2003-09-11 | Medimmune Limited | Pyrrolobenzodiazepines |
DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
GB0226593D0 (en) | 2002-11-14 | 2002-12-24 | Consultants Ltd | Compounds |
GB0416511D0 (en) | 2003-10-22 | 2004-08-25 | Spirogen Ltd | Pyrrolobenzodiazepines |
PL2270010T3 (pl) | 2004-03-01 | 2012-07-31 | Medimmune Ltd | Pochodne 11-hydroksy-5h-pirolo[2,1-c][1,4]benzodiazepin-5-onu jako kluczowe związki pośrednie do otrzymywania c2 podstawionych pirolobenzodiazepin |
GB0404578D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
GB0404577D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
US7528126B2 (en) | 2004-03-09 | 2009-05-05 | Spirogen Limited | Pyrrolobenzodiazepines |
NZ563136A (en) | 2005-04-21 | 2009-11-27 | Spirogen Ltd | Pyrrolobenzodiazepines |
JP2009509510A (ja) | 2005-09-26 | 2009-03-12 | メダレックス インコーポレーティッド | Cd70に対するヒトモノクローナル抗体 |
KR101446510B1 (ko) | 2005-12-08 | 2014-10-20 | 메다렉스, 엘.엘.시. | 푸코실-지엠1에 대한 인간 모노클론 항체 및 항-푸코실-지엠1 사용법 |
RS52060B (en) | 2006-01-25 | 2012-04-30 | Sanofi | CYTOTOXIC AGENTS CONTAINING NEW TOMAIMYCIN DERIVATIVES |
SI2178921T1 (sl) | 2007-07-17 | 2016-05-31 | E.R. Squibb & Sons, L.L.C. | Monoklonska protitelesa proti glipikan-3 |
SI2019104T1 (sl) | 2007-07-19 | 2013-12-31 | Sanofi | Citotoksična sredstva, ki obsegajo nove tomaimicinske derivate, in njihova terapevtska uporaba |
WO2009045957A1 (en) | 2007-10-01 | 2009-04-09 | Medarex, Inc. | Human antibodies that bind mesothelin, and uses thereof |
GB0813432D0 (en) | 2008-07-22 | 2008-08-27 | Spirogen Ltd | Pyrrolobenzodiazepines |
GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
NZ594177A (en) * | 2009-02-05 | 2014-02-28 | Immunogen Inc | Novel benzodiazepine derivatives |
FR2949469A1 (fr) | 2009-08-25 | 2011-03-04 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application en therapeutique |
MX2012011900A (es) | 2010-04-15 | 2013-03-21 | Seattle Genetics Inc | Conjugados de pirrolobenzodiazepina diana. |
NZ602933A (en) | 2010-04-15 | 2014-09-26 | Seattle Genetics Inc | Pyrrolobenzodiazepines used to treat proliferative diseases |
EA024730B1 (ru) | 2010-04-15 | 2016-10-31 | Медимьюн Лимитед | Пирролбензодиазепиновые соединения, их конъюгаты, фармацевтические композиции, содержащие указанные конъюгаты, и применение указанных конъюгатов |
FR2963007B1 (fr) | 2010-07-26 | 2013-04-05 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application therapeutique |
SI2675480T1 (sl) * | 2011-02-15 | 2019-05-31 | Immunogen, Inc. | Metode priprave konjugatov |
CN103987718A (zh) | 2011-09-20 | 2014-08-13 | 斯皮罗根有限公司 | 作为非对称二聚体pbd化合物用于内含在靶向结合物中的吡咯并苯并二氮杂卓 |
CN103998450B (zh) | 2011-10-14 | 2017-03-08 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓 |
US9526798B2 (en) | 2011-10-14 | 2016-12-27 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
KR101961976B1 (ko) | 2011-10-14 | 2019-03-25 | 시애틀 지네틱스, 인크. | 피롤로벤조디아제핀 및 표적 접합체 |
PT2750713E (pt) | 2011-10-14 | 2016-01-20 | Genentech Inc | Pirrolobenzodiazepinas e conjugados das mesmas |
US9388187B2 (en) | 2011-10-14 | 2016-07-12 | Medimmune Limited | Pyrrolobenzodiazepines |
WO2013177481A1 (en) | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazepines and conjugates thereof |
WO2014031566A1 (en) | 2012-08-22 | 2014-02-27 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives |
JP5993093B2 (ja) | 2012-10-12 | 2016-09-14 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピン類およびその複合体 |
NZ745069A (en) | 2012-10-12 | 2019-05-31 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
US10131682B2 (en) | 2012-11-24 | 2018-11-20 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules |
US9567340B2 (en) | 2012-12-21 | 2017-02-14 | Medimmune Limited | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases |
EA031585B1 (ru) | 2012-12-21 | 2019-01-31 | Медимьюн Лимитед | Пирролобензодиазепины и их конъюгаты |
CA2904044C (en) | 2013-03-13 | 2020-03-31 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
SG11201507214SA (en) | 2013-03-13 | 2015-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
NZ712035A (en) | 2013-03-13 | 2019-06-28 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
US20160106861A1 (en) | 2013-04-26 | 2016-04-21 | Spirogen Sarl | Axl antibody-drug conjugate and its use for the treatment of cancer |
-
2016
- 2016-01-13 CN CN201680006151.5A patent/CN107428780B/zh active Active
- 2016-01-13 EP EP16703196.2A patent/EP3245213B1/en active Active
- 2016-01-13 US US14/994,296 patent/US9527871B2/en active Active
- 2016-01-13 MX MX2017009145A patent/MX2017009145A/es unknown
- 2016-01-13 EA EA201791550A patent/EA201791550A1/ru unknown
- 2016-01-13 CA CA2973354A patent/CA2973354A1/en not_active Abandoned
- 2016-01-13 TW TW105100987A patent/TW201632531A/zh unknown
- 2016-01-13 WO PCT/US2016/013136 patent/WO2016115191A1/en active Application Filing
- 2016-01-13 ES ES16703196T patent/ES2783624T3/es active Active
- 2016-01-13 KR KR1020177022244A patent/KR20170102980A/ko not_active Application Discontinuation
- 2016-01-13 AU AU2016206798A patent/AU2016206798A1/en not_active Abandoned
- 2016-01-13 PE PE2017001216A patent/PE20171184A1/es unknown
- 2016-01-13 JP JP2017537227A patent/JP6498773B2/ja active Active
- 2016-01-13 SG SG11201705646XA patent/SG11201705646XA/en unknown
- 2016-01-13 BR BR112017014599A patent/BR112017014599A2/pt not_active Application Discontinuation
- 2016-11-15 US US15/351,843 patent/US9676794B2/en active Active
-
2017
- 2017-05-05 US US15/587,715 patent/US9822144B2/en active Active
- 2017-07-10 IL IL253402A patent/IL253402A0/en unknown
- 2017-07-13 ZA ZA2017/04738A patent/ZA201704738B/en unknown
- 2017-07-13 CL CL2017001824A patent/CL2017001824A1/es unknown
- 2017-08-10 CO CONC2017/0008078A patent/CO2017008078A2/es unknown
- 2017-10-17 US US15/785,675 patent/US10112975B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP6498773B2 (ja) | 2019-04-10 |
US20170233436A1 (en) | 2017-08-17 |
CN107428780B (zh) | 2020-09-04 |
US10112975B2 (en) | 2018-10-30 |
BR112017014599A2 (pt) | 2018-01-16 |
IL253402A0 (en) | 2017-09-28 |
CA2973354A1 (en) | 2016-07-21 |
KR20170102980A (ko) | 2017-09-12 |
ES2783624T3 (es) | 2020-09-17 |
US20170073357A1 (en) | 2017-03-16 |
US9822144B2 (en) | 2017-11-21 |
TW201632531A (zh) | 2016-09-16 |
EP3245213B1 (en) | 2020-03-04 |
ZA201704738B (en) | 2019-02-27 |
JP2018503639A (ja) | 2018-02-08 |
EP3245213A1 (en) | 2017-11-22 |
MX2017009145A (es) | 2017-11-22 |
US9676794B2 (en) | 2017-06-13 |
SG11201705646XA (en) | 2017-08-30 |
US20160200742A1 (en) | 2016-07-14 |
PE20171184A1 (es) | 2017-08-22 |
CL2017001824A1 (es) | 2018-02-09 |
US20180079781A1 (en) | 2018-03-22 |
WO2016115191A1 (en) | 2016-07-21 |
CO2017008078A2 (es) | 2017-11-10 |
US9527871B2 (en) | 2016-12-27 |
AU2016206798A1 (en) | 2017-08-31 |
CN107428780A (zh) | 2017-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201791550A1 (ru) | Димеры бензодиазепинов, их конъюгаты и способы их получения и применения | |
EA201791461A1 (ru) | Бензодиазепиновые димеры с мостиковым гетероариленом, их конъюгаты, способы получения и применение | |
EA201990615A1 (ru) | Пирролобензодиазепиновые конъюгаты | |
CY1120581T1 (el) | Ενωσεις και μεθοδοι χρησης τους | |
EA202091508A1 (ru) | 6-азаиндольные соединения | |
CY1120480T1 (el) | Ενωσεις πυραζολοπυριμιδινης | |
MX2023001582A (es) | Conjugados proteina-polimero-farmaco. | |
MX367851B (es) | Conjugados de proteína-polímero-fármaco. | |
BR112018003269A2 (pt) | conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização | |
EA202091484A1 (ru) | 4-азаиндольные соединения | |
EA201591317A1 (ru) | Соединения тубулизина, способы их получения и применение | |
EA201791692A1 (ru) | 4H-ПИРРОЛО[3,2-c]ПИРИДИН-4-ОНОВЫЕ ПРОИЗВОДНЫЕ | |
EA201270308A1 (ru) | Конъюгаты димеров пирроло [1,4]бензодиазепина в качестве противоракового средства | |
EA201591497A1 (ru) | Новые производные октагидропирроло[3,4-c]пиррола и их аналоги в качестве ингибиторов аутотаксина | |
EA201590534A1 (ru) | Новые бициклические производные | |
EA201491447A1 (ru) | Ендиины, их конъюгаты и способы их получения и применения | |
PE20150892A1 (es) | Anticuerpos anti-notch y conjugados de anticuerpo-farmaco | |
EA201691272A1 (ru) | Тетрагидропиридопиразины в качестве модуляторов gpr6 | |
EA201170227A1 (ru) | Имидазолкарбоксамиды | |
CR20170111A (es) | Derivados de benzodiazepina citotóxicos | |
EA201490567A1 (ru) | Новые бициклические производные дигидрохинолин-2-она | |
MA38982A1 (fr) | Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl | |
EA201792516A1 (ru) | Макроциклические димеры бензодиазепина, их конъюгаты, получение и применение | |
BR112018010279A2 (pt) | novos anticorpos anti-emr2 e métodos de uso | |
EA201490846A1 (ru) | Новые производные арилхинолина |